Silexion strikes warrant inducement deal to raise about $0.84 million

Silexion Therapeutics Corp entered into an inducement offer letter agreement on September 28, 2026 with holders of 3,216,928 series E warrants that had been issued in the company's public offering completed on August 11, 2026 and originally carried a five-year term with a $0.65 exercise price.

Under the agreement, those holders agreed to exercise their warrants in cash at a lowered price of $0.2603 per share, in exchange for Silexion issuing new share purchase warrants covering up to 6,433,856 shares at the same $0.2603 price.¹ The new warrants are split evenly between 3,216,928 Series F warrants and 3,216,928 Series G warrants.¹

Silexion said it anticipates gross proceeds of roughly $0.84 million from the warrant exercises, before subtracting placement agent fees and other costs of the offering.¹ H.C. Wainwright & Co., LLC is serving as placement agent and will receive a 7.0% cash fee plus a 1.0% management fee on gross proceeds from the exercise of the existing warrants.¹ The agent will also receive warrants to buy up to 225,185 shares, priced at $0.3254, equal to 125% of the reduced exercise price.¹

Closing of the transaction is expected on or about September 29, 2026, subject to customary closing conditions.¹ Silexion also agreed to file a resale registration statement for the new warrant shares within 30 days of the letter's date, and to pursue SEC effectiveness within 60 to 90 days depending on review type.¹

Separately, in connection with the offering's closing, Silexion is cutting the exercise price on all outstanding series E warrants, covering 3,846,161 shares, to $0.2603 per share, applying the reduction to the existing warrants held by participating investors as well as to other outstanding series E warrants.¹